Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Clinical Cancer Research|2019Cited by 40
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft modelsChi-Heng Wu, Weiyun Z. Ai, Linlin Wang et al.|Blood Advances|2021Cited by 33
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Weiyun Z. Ai, Linlin Wang et al.|Journal of Investigative Dermatology|2020Cited by 21
Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary SyndromeWeiyun Z. Ai, Frank McCormick, Chen‐Yen Yang et al.|Blood|2015Cited by 2
Table and Fig from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0